Lexicon Pharmaceuticals, Inc.
LXRX
$2.32
-$0.02-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1,077.09% | 95.88% | 54.01% | 80.30% | 106.09% |
| Total Depreciation and Amortization | -42.05% | -37.50% | -5.60% | 19.84% | 26.62% |
| Total Amortization of Deferred Charges | 32.34% | 69.83% | 23.44% | 0.00% | -23.43% |
| Total Other Non-Cash Items | 279.44% | 993.22% | 11,847.37% | 176.59% | 7,940.00% |
| Change in Net Operating Assets | 29.54% | 14.68% | -138.65% | -247.70% | 163.60% |
| Cash from Operations | -154.09% | 66.35% | 19.81% | 55.55% | 135.01% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -206.32% | -273.14% | -91.08% | -3.07% | 228.24% |
| Cash from Investing | -206.32% | -273.14% | -91.01% | -2.51% | 225.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -20.58% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -397.03% | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 98.86% | 15,616.78% | -2,714.42% | 100.00% | -321,328.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -108.92% | 199.87% | -147.75% | 2,754.03% | 79.43% |